BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Chen KW, Ou TM, Hsu CW, Horng CT, Lee CC, Tsai YY, Tsai CC, Liou YS, Yang CC, Hsueh CW, Kuo WH. Current systemic treatment of hepatocellular carcinoma: A review of the literature. World J Hepatol 2015; 7(10): 1412-1420 [PMID: 26052386 DOI: 10.4254/wjh.v7.i10.1412]
URL: https://www.wjgnet.com/1948-5182/full/v7/i10/1412.htm
Number Citing Articles
1
Xuan Jing, Hongping Liang, Xiangrong Cui, Chongyang Han, Chonghua Hao, Kai Huo. Long noncoding RNA CCAT2 can predict metastasis and a poor prognosis: A meta-analysisClinica Chimica Acta 2017; 468: 159 doi: 10.1016/j.cca.2017.03.003
2
Michael L Caparelli, Nathan J Roberts, Timothy S Braverman, Robert M Stevens, Edward R Broun, Shyam Allamaneni. Metastatic recurrence to a solitary lymph node four years after hepatic lobectomy for primary hepatocellular carcinomaWorld Journal of Hepatology 2016; 8(23): 994-998 doi: 10.4254/wjh.v8.i23.994
3
Julie K. Heimbach, Laura M. Kulik, Richard S. Finn, Claude B. Sirlin, Michael M. Abecassis, Lewis R. Roberts, Andrew X. Zhu, M. Hassan Murad, Jorge A. Marrero. AASLD guidelines for the treatment of hepatocellular carcinomaHepatology 2018; 67(1): 358 doi: 10.1002/hep.29086
4
Ayse Banu Demir, Elif Baris, Umay Bengi Kaner, Hani Alotaibi, Nese Atabey, Ahmet Koc. Toll-interacting protein may affect doxorubicin resistance in hepatocellular carcinoma cell linesMolecular Biology Reports 2023; 50(10): 8551 doi: 10.1007/s11033-023-08737-2
5
Sandro Nuciforo, Isabel Fofana, Matthias S. Matter, Tanja Blumer, Diego Calabrese, Tujana Boldanova, Salvatore Piscuoglio, Stefan Wieland, Femke Ringnalda, Gerald Schwank, Luigi M. Terracciano, Charlotte K.Y. Ng, Markus H. Heim. Organoid Models of Human Liver Cancers Derived from Tumor Needle BiopsiesCell Reports 2018; 24(5): 1363 doi: 10.1016/j.celrep.2018.07.001
6
Bang-Bin Chen, Chao-Yu Hsu, Chih-Wei Yu, Po-Chin Liang, Chiun Hsu, Chih-Hung Hsu, Ann-Lii Cheng, Tiffany Ting-Fang Shih. Early perfusion changes within 1 week of systemic treatment measured by dynamic contrast-enhanced MRI may predict survival in patients with advanced hepatocellular carcinomaEuropean Radiology 2017; 27(7): 3069 doi: 10.1007/s00330-016-4670-2
7
Zhenluo Jiang, Lili Shen, Shuwei Wang, Shengdong Wu, Yaoren Hu, Junming Guo, Liyun Fu. Hsa_circ_0028502 and hsa_circ_0076251 are potential novel biomarkers for hepatocellular carcinomaCancer Medicine 2019; 8(17): 7278 doi: 10.1002/cam4.2584
8
Mohamed M. Tawfik, Nourhan Eissa, Fayez Althobaiti, Eman Fayad, Ali H. Abu Almaaty. Nomad Jellyfish Rhopilema nomadica Venom Induces Apoptotic Cell Death and Cell Cycle Arrest in Human Hepatocellular Carcinoma HepG2 CellsMolecules 2021; 26(17): 5185 doi: 10.3390/molecules26175185
9
Justin Hartke, Matthew Johnson, Marwan Ghabril. The diagnosis and treatment of hepatocellular carcinomaSeminars in Diagnostic Pathology 2017; 34(2): 153 doi: 10.1053/j.semdp.2016.12.011
10
Zhenluo Jiang, Shuwei Wang, Jiancheng Jin, Sheng Ying, Zhigang Chen, Dedong Zhu, Bingxiu Xiao, Yaoren Hu, Yunsong Qian, Ting Cai, Liyun Fu. The clinical significance of serum chitinase 3‐like 1 in hepatitis B–related chronic liver diseasesJournal of Clinical Laboratory Analysis 2020; 34(5) doi: 10.1002/jcla.23200
11
Annie K Hung, Jennifer Guy. Hepatocellular carcinoma in the elderly: Meta-analysis and systematic literature reviewWorld Journal of Gastroenterology 2015; 21(42): 12197-12210 doi: 10.3748/wjg.v21.i42.12197
12
Xianwei Zhang, Hu Zhou, Wei Jing, Ping Luo, Shili Qiu, Xuefang Liu, Man Zhu, Chunzi Liang, Mingxia Yu, Jiancheng Tu. The Circular RNA hsa_circ_0001445 Regulates the Proliferation and Migration of Hepatocellular Carcinoma and May Serve as a Diagnostic BiomarkerDisease Markers 2018; 2018: 1 doi: 10.1155/2018/3073467
13
Muhammad Raza Shah, Muhammad Imran, Shafi Ullah. Nanocarriers for Cancer Diagnosis and Targeted Chemotherapy2019; : 79 doi: 10.1016/B978-0-12-816773-1.00004-3
14
Mahfoozur Rahman, Waleed H Almalki, Majed Alrobaian, Jawed Iqbal, Saad Alghamdi, Khalid S Alharbi, Nabil K Alruwaili, Abdul Hafeez, Adil Shaharyar, Tanuja Singh, Mohammad Waris, Vikas Kumar, Sarwar Beg. Nanocarriers-loaded with natural actives as newer therapeutic interventions for treatment of hepatocellular carcinomaExpert Opinion on Drug Delivery 2021; 18(4): 489 doi: 10.1080/17425247.2021.1854223
15
Mingang He, Wenchao Gu, Yang Gao, Ying Liu, Jie Liu, Zengjun Li. Molecular subtypes and a prognostic model for hepatocellular carcinoma based on immune- and immunogenic cell death-related lncRNAsFrontiers in Immunology 2022; 13 doi: 10.3389/fimmu.2022.1043827
16
Peng-Sheng Yi, Min Huang, Ming Zhang, Liangliang Xu, Ming-Qing Xu. Comparison of Transarterial Chemoembolization Combined with Radiofrequency Ablation Therapy versus Surgical Resection for Early Hepatocellular CarcinomaThe American Surgeon 2018; 84(2): 282 doi: 10.1177/000313481808400238
17
Shashank Kumar, Abhay Kumar Pandey. Potential Molecular Targeted Therapy for Unresectable Hepatocellular CarcinomaCurrent Oncology 2023; 30(2): 1363 doi: 10.3390/curroncol30020105
18
Yuee Cai, Yingqi Xu, Hon Fai Chan, Xiaobin Fang, Chengwei He, Meiwan Chen. Glycyrrhetinic Acid Mediated Drug Delivery Carriers for Hepatocellular Carcinoma TherapyMolecular Pharmaceutics 2016; 13(3): 699 doi: 10.1021/acs.molpharmaceut.5b00677
19
Xing Wang, Haisheng Guo, Weixin Liu, Chunmei Yang, Lei Yang, Dongguan Wang, Xunguo Wang. Effects of siRNA-Mediated Knockdown of HDAC1 on the Biological Behavior of Esophageal Carcinoma Cell LinesMedical Science Monitor 2016; 22: 1291 doi: 10.12659/MSM.895853
20
Mingfang Wu, Bolin Lian, Yiping Deng, Ziqi Feng, Chen Zhong, Weiwei Wu, Yannian Huang, Lingling Wang, Chang Zu, Xiuhua Zhao. Resveratrol-loaded glycyrrhizic acid-conjugated human serum albumin nanoparticles wrapping resveratrol nanoparticles: Preparation, characterization, and targeting effect on liver tumorsJournal of Biomaterials Applications 2017; 32(2): 191 doi: 10.1177/0885328217713357
21
Wafaa M. Rashed, Mohamed Ahmed Mohamed Kandeil, Mohamed O. Mahmoud, Sameera Ezzat. Hepatocellular Carcinoma (HCC) in Egypt: A comprehensive overviewJournal of the Egyptian National Cancer Institute 2020; 32(1) doi: 10.1186/s43046-020-0016-x
22
Fan-Yun Kong, Xiao Wei, Kai Zhou, Wei Hu, Yan-Bo Kou, Hong-Juan You, Xiao-Mei Liu, Kui-Yang Zheng, Ren-Xian Tang, Jason Blackard. Bioinformatics Analysis Reveals Distinct Molecular Characteristics of Hepatitis B-Related Hepatocellular Carcinomas from Very Early to Advanced Barcelona Clinic Liver Cancer StagesPLOS ONE 2016; 11(7): e0158286 doi: 10.1371/journal.pone.0158286
23
Chao Meng, Xiaomin Shen, Wentao Jiang. Potential biomarkers of HCC based on gene expression and DNA methylation profilesOncology Letters 2018;  doi: 10.3892/ol.2018.9020
24
I-Tao Huang, Bijay Dhungel, Ritu Shrestha, Kim R. Bridle, Darrell H. G. Crawford, Aparna Jayachandran, Jason C Steel. Spotlight on Bortezomib: potential in the treatment of hepatocellular carcinomaExpert Opinion on Investigational Drugs 2019; 28(1): 7 doi: 10.1080/13543784.2019.1551359
25
Lumin Chen, Jihong Sun, Xiaoming Yang. Radiofrequency ablation-combined multimodel therapies for hepatocellular carcinoma: Current statusCancer Letters 2016; 370(1): 78 doi: 10.1016/j.canlet.2015.09.020
26
Meng-Hua Chung, Shu-Yi Wang, Chia-Chin Lin. Symptom Clusters and Impact of Fatigue and Sleep Disturbance on Symptom Experiences of Hepatoma Patients in TaiwanCancer Nursing 2017; 40(5): 403 doi: 10.1097/NCC.0000000000000417
27
Niki Vassilaki, Efseveia Frakolaki. Virus–host interactions under hypoxiaMicrobes and Infection 2017; 19(3): 193 doi: 10.1016/j.micinf.2016.10.004
28
Umesh Tharehalli, Michael Svinarenko, André Lechel. Remodelling and Improvements in Organoid Technology to Study Liver Carcinogenesis in a DishStem Cells International 2019; 2019: 1 doi: 10.1155/2019/3831213
29
Mingao Zhu. Inhibitory effects of bortezomib in a subcutaneous tumor model of H22 mouse hepatocarcinoma cellsPathology - Research and Practice 2019; 215(6): 152388 doi: 10.1016/j.prp.2019.03.017
30
Daniel Hughes, Aron Hughes, Bilal Al-Sarireh. Hepatocellular carcinoma’s 100 most influential manuscripts: A bibliometric analysisInternational Journal of Hepatobiliary and Pancreatic Diseases 2019; 9(2): 1 doi: 10.5348/100083Z04DH2019OA
31
Chao Wu, Hongwei Kan, Min Hu, Xin Liu, Alex Boye, Yufeng Jiang, Jiajun Wu, Jiyu Wang, Xiaochuan Yang, Yan Yang. Compound Astragalus and Salvia miltiorrhiza extract inhibits hepatocarcinogenesis via modulating TGF‑β/TβR and Imp7/8Experimental and Therapeutic Medicine 2018;  doi: 10.3892/etm.2018.6292
32
Mengxiao Chen, Huaying Huang, Yujin Pan, Zhenzhen Li, Si Ouyang, Changjing Ren, Qiang Zhao. Preparation of layering-structured magnetic fluorescent liposomes and labeling of HepG2 cellsBio-Medical Materials and Engineering 2022; 33(2): 147 doi: 10.3233/BME-228000
33
Ping Luo, Sanyun Wu, Yalan Yu, Xinliang Ming, Shuo Li, Xuelan Zuo, Jiancheng Tu. Current Status and Perspective Biomarkers in AFP Negative HCC: Towards Screening for and Diagnosing Hepatocellular Carcinoma at an Earlier StagePathology & Oncology Research 2020; 26(2): 599 doi: 10.1007/s12253-019-00585-5
34
Yu-Lan Li, Xiao-Min Zhu, Hong Liang, Chris Orvig, Zhen-Feng Chen. Recent Advances in Asialoglycoprotein Receptor and Glycyrrhetinic Acid Receptor-Mediated and/or pH-Responsive Hepatocellular Carcinoma- Targeted Drug DeliveryCurrent Medicinal Chemistry 2021; 28(8): 1508 doi: 10.2174/0929867327666200505085756
35
Ping Huang, Yu Hua Zhang, Xiao Wei Zheng, Yu Jia Liu, Hong Zhang, Luo Fang, Yi Wen Zhang, Chang Yang, Khairul Islam, Chao Wang, Hua Naranmandura. Phenylarsine oxide (PAO) induces apoptosis in HepG2 cellsviaROS-mediated mitochondria and ER-stress dependent signaling pathwaysMetallomics 2017; 9(12): 1756 doi: 10.1039/C7MT00179G
36
Wei Jing, Shanshan Gao, Man Zhu, Ping Luo, Xuan Jing, Hongyan Chai, Jiancheng Tu. Potential diagnostic value of lncRNA SPRY4-IT1 in hepatocellular carcinomaOncology Reports 2016; 36(2): 1085 doi: 10.3892/or.2016.4859
37
Wenbin Ding, Haixia Yang, Shenchu Gong, Weixiang Shi, Jing Xiao, Jinhua Gu, Yilang Wang, Bosheng He. Candidate miRNAs and pathogenesis investigation for hepatocellular carcinoma based on bioinformatics analysisOncology Letters 2017; 13(5): 3409 doi: 10.3892/ol.2017.5913
38
Houyong Long, Xingjun Guo, Shen Qiao, Qingxing Huang. Tumor LXR Expression is a Prognostic Marker for Patients with Hepatocellular CarcinomaPathology & Oncology Research 2018; 24(2): 339 doi: 10.1007/s12253-017-0249-8
39
Jiale Ju, Yinghua Wu, Wen He, Lin Zhan, Xuelian Yin, Junfeng Zhang, Yuxi Zhang, Li Qiu, Pir Muhammad, Rui L. Reis, Chenchen Li. Nanocarriers for Active Ingredients of Chinese Medicine (AIFCM) Used in Gastrointestinal Cancer TherapyJournal of Biomedical Nanotechnology 2022; 18(10): 2279 doi: 10.1166/jbn.2022.3446
40
Christos Damaskos, Nikolaos Garmpis, Dimitrios Dimitroulis, Anna Garmpi, Iason Psilopatis, Panagiotis Sarantis, Evangelos Koustas, Prodromos Kanavidis, Dionysios Prevezanos, Gregory Kouraklis, Michail V. Karamouzis, Georgios Marinos, Konstantinos Kontzoglou, Efstathios A. Antoniou. Targeted Therapies for Hepatocellular Carcinoma Treatment: A New Era Ahead—A Systematic ReviewInternational Journal of Molecular Sciences 2022; 23(22): 14117 doi: 10.3390/ijms232214117
41
Guang Song, Hong-Xia Cao, Shao-Xin Yao, Cang-Tuo Li. Abnormal expression of WIF1 in hepatocellular carcinoma cells and its regulating effect on invasion and metastasis factors of TIMP-3 and caveolin-1 of hepatocellular carcinomaAsian Pacific Journal of Tropical Medicine 2015; 8(11): 958 doi: 10.1016/j.apjtm.2015.10.007
42
Meiwan Chen, Xingzhi Zhou, Ruie Chen, Junlin Wang, Richard D. Ye, Yitao Wang, Chuanbin Wu, Ram I. Mahato. Nano-carriers for delivery and targeting of active ingredients of Chinese medicine for hepatocellular carcinoma therapyMaterials Today 2019; 25: 66 doi: 10.1016/j.mattod.2018.10.040